Regional patterns of atrophy on MRI in Alzheimer’s disease: Neuropsychological features and progression rates in the ADNI cohort

DOI: 10.4236/aad.2013.24019   PDF   HTML     4,733 Downloads   8,321 Views   Citations


Background: Discrete clinical and pathological subtypes of Alzheimer’s disease (AD) with variable presentations and rates of progression are well known. These subtypes may have specific patterns of regional brain atrophy, which are identifiable on MRI scans. Methods: To examine distinct regions which had distinct underlying patterns of cortical atrophy, factor analytic techniques applied to structural MRI volumetric data from cognitively normal (CN) (n = 202), amnestic mild cognitive impairment (aMCI) (n = 333) or mild AD (n = 146) subjects, in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database was applied. This revealed the existence of two neocortical (NeoC-1 and NeoC-2), and a limbic cluster of atrophic brain regions. The frequency and clinical correlates of these regional patterns of atrophy were evaluated among the three diagnostic groups, and the rates of progression from aMCI to AD, over 24 months were evaluated. Results: Discernable patterns of regional atrophy were observed in about 29% of CN, 55% of aMCI and 83% of AD subjects. Heterogeneity in clinical presentation and APOE ε4 frequency were associated with regional patterns of atrophy on MRI scans. The most rapid progression rates to dementia among aMCI subjects (n = 224), over a 24-month period, were in those with NeoC-1 regional impairment (68.2%), followed by the Limbic regional impairment (48.8%). The same pattern of results was observed when only aMCI amyloid positive subjects were examined. Conclusions: The neuroimaging results closely parallel findings described recently among AD patients with the hippocampal sparing and limbic subtypes of AD neuropathology at autopsy. We conclude that NeoC-1, Limbic and other patterns of MRI atrophy may be useful markers for predicting the rate of progression of aMCI to AD and could have utility selecting individuals at higher risk for progression in clinical trials.

Share and Cite:

Duara, R. , Loewenstein, D. , Shen, Q. , Barker, W. , Greig, M. , Varon, D. , Murray, M. and Dickson, D. (2013) Regional patterns of atrophy on MRI in Alzheimer’s disease: Neuropsychological features and progression rates in the ADNI cohort. Advances in Alzheimer's Disease, 2, 135-147. doi: 10.4236/aad.2013.24019.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Komarova, N.L. and Thalhauser, C.J. (2011) High degree of heterogeneity in Alzheimer’s disease progression patterns. PLOS Computational Biology, 7, Article ID: e1002251.
[2] Murray, M.E., Graff-Radford, N.R., Ross, O.A., Petersen, R.C., Duara, R. and Dickson, D.W. (2011) Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: A retrospective study. The Lancet Neurology, 10, 785-796.
[3] Jack Jr., C.R., Shiung, M.M., Gunter, J.L., et al. (2004) Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology, 62, 591-600.
[4] Misra, C., Fan, Y. and Davatzikos, C. (2009) Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI. Neuroimage, 44, 1415-1422.
[5] Evans, M.C., Barnes, J., Nielsen, C., et al. (2010) Volume changes in Alzheimer’s disease and mild cognitive impairment: Cognitive associations. European Radiology, 20, 674-682.
[6] Hua, X., Lee, S., Hibar, D.P., et al. (2010) Mapping Alzheimer’s disease progression in 1309 MRI scans: Power estimates for different inter-scan intervals. Neuroimage, 51, 63-75.
[7] Frisoni, G.B., Fox, N.C., Jack Jr., C.R., Scheltens, P. and Thompson, P.M. (2010) The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 6, 67-77.
[8] Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
[9] Morris, J.C. (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology, 43, 2412- 2414.
[10] Rey, A. (1964) L’examen clinique en psychologie. Presses Univeritaires de France, Paris.
[11] Buckner, R.L., Snyder, A.Z., Shannon, B.J., et al. (2005) Molecular, structural, and functional characterization of Alzheimer’s disease: Evidence for a relationship between default activity, amyloid, and memory. The Journal of Neuroscience, 25, 7709-7717.
[12] Sheline, Y.I., Raichle, M.E., Snyder, A.Z., et al. (2010) Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biological Psychiatry, 67, 584-587.
[13] Sheline, Y.I., Morris, J.C., Snyder, A.Z., et al. (2010) APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. The Journal of Neuro-science, 30, 17035-17040.
[14] Mars, R.B., Sallet, J., Schuffelgen, U., Jbabdi, S., Toni, I. and Rushworth, M.F. (2012) Connectivity-based subdivisions of the human right “temporoparietal junction area”: Evidence for different areas participating in different cortical networks. Cerebral Cortex, 22, 1894-1903.
[15] Spreng, R.N., Mar, R.A. and Kim, A.S. (2009) The common neural basis of autobiographical memory, prospection, navigation, theory of mind, and the default mode: A quantitative meta-analysis. Journal of Cognitive Neuroscience, 21, 489-510.
[16] Sperling, R.A., Aisen, P.S., Beckett, L.A., et al. (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7, 280-292.
[17] Morris, J.C. (2006) Mild cognitive impairment is early-stage Alzheimer disease: Time to revise diagnostic criteria. Archives of Neurology, 63, 15-16.
[18] Duara, R., Loewenstein, D.A., Greig, M.T., et al. (2011) Pre-MCI and MCI: Neuropsychological, clinical, and imaging features and progression rates. The American Journal of Geriatric Psychiatry, 19, 951-960.
[19] Dickerson, B.C. and Wolk, D.A. (2012) MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology, 78, 84-90.
[20] Saykin, A.J., Shen, L., Foroud, T.M., et al. (2010) Alzheimer’s disease neuroimaging initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimer’s & Dementia, 6, 265-273.
[21] Holland, D., Brewer, J.B., Hagler, D.J., Fennema-Notestine, C. and Dale, A.M. (2009) Subregional neuroanatomical change as a biomarker for Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 106, 20954-20959.
[22] Loewenstein, D.A., Greig, M.T., Schinka, J.A., et al. (2012) An investigation of PreMCI: Subtypes and longitudinal outcomes. Alzheimer’s & Dementia, 8, 172-179.
[23] Scahill, R.I., Schott, J.M., Stevens, J.M., Rossor, M.N. and Fox, N.C. (2002) Mapping the evolution of regional atrophy in Alzheimer’s disease: Unbiased analysis of fluid-registered serial MRI. Proceedings of the National Academy of Sciences of the United States of America, 99, 4703-4707.
[24] Risacher, S.L., Shen, L., West, J.D., et al. (2010) Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort. Neurobiology of Aging, 31, 1401-1418.
[25] Spreen, O. and Strauss, E. (1998) A compendium of neuropsychological tests: Administration, norms, and commentary. 2nd Edition, Oxford University Press, New York.
[26] Jagust, W.J., Landau, S.M., Shaw, L.M., et al. (2009) Relationships between biomarkers in aging and dementia. Neurology, 73, 1193-1199.
[27] Desikan, R.S., Cabral, H.J., Settecase, F., et al. (2010) Automated MRI measures predict progression to Alzheimer’s disease. Neurobiology of Aging, 31, 1364-1374.
[28] Desikan, R.S., Segonne, F., Fischl, B., et al. (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage, 31, 968-980.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.